Ratio Therapeutics, a US-based clinical-stage developer of radiopharmaceuticals for cancer treatment, has closed a $70m Series C financing round. The funding will be used to advance its ATLAS clinical trial, which is assessing its lead candidate [Ac-225]RTX-2358, a fibroblast activation protein (FAP)-targeted radiotherapeutic, for patients with advanced sarcomas. Ratio Therapeutics plans to expand its discovery pipeline to additional cancer targets and apply its technology to new tumour types that are not currently being addressed. This approach is designed to provide flexible clinical and potential commercial supply as the company expands its radiopharmaceutical pipeline. "Ratio Therapeutics secures $70m Series C funding for cancer radiotherapy" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.